UK markets closed

AGEN Jan 2025 1.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.06000.0000 (0.00%)
At close: 09:59AM EDT
Full screen
Previous close0.0600
Open0.0600
Bid0.0000
Ask0.0000
Strike1.50
Expiry date2025-01-17
Day's range0.0600 - 0.0600
Contract rangeN/A
Volume9
Open interest1.25k
  • Business Wire

    Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50

    LEXINGTON, Mass., June 13, 2024--Agenus has published results from a groundbreaking clinical trial in Nature Medicine, revealing the potential of a novel immunotherapy combination for treating microsatellite stable metastatic colorectal cancer (MSS mCRC), a cancer type historically resistant to immunotherapy. This pioneering research, led by an international team of oncologists, focuses on the efficacy and safety of botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination with bal

  • Business Wire

    Agenus Announces Virtual Annual Shareholders Meeting

    LEXINGTON, Mass., June 04, 2024--Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 11, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.

  • Business Wire

    Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LEXINGTON, Mass., May 24, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted inducement awards to Eric Olson, in connection with his appointment as Head of Regulatory. The Compensation Committee approved the awards pursuant to Agenus' 2015 Inducement Equity Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).